Target Markets Focus on expanding within Occupational Health, Optometry, DMV, hospitals, and primary care networks in the US, leveraging Depisteo’s VT1 vision screener and Spirolyser Q13 spirometer to address routine screening, pre-employment health checks, and respiratory/vision assessments.

Compact Solutions Highlight the lightweight, self-contained design and rapid 3-5 minute screening time of VT1, plus the no-contact, single-use Fleisch sensor of Spirolyser Q13, to appeal to clinics seeking efficient, hygienic point-of-care devices with minimal downtime.

Customization & Automation Promote customizable test sequences and automated pass/fail scoring to reduce clinician workload, enabling practices with limited staff to scale screening capabilities without sacrificing accuracy or compliance.

US Subsidiary Advantage Position Depisteo LLC as a US-based subsidiary of a larger European group, emphasizing local support, faster onboarding, and potential access to broader FIM Medical product ecosystem for bundle sales and cross-sell opportunities.

Low Revenue Growth Upsell With current revenue under one million, pursue cross-sell and up-sell to mid-size clinics and small hospital networks, offering bundled equipment, extended warranties, training services, and software subscriptions to increase average deal size.